Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00209898
Status:
TERMINATED
Last Update Posted:
2015-03-20
First Post:
2005-09-13
Brief Title:
Hepatitis C Treatment of Inmates
Sponsor:
Haukeland University Hospital
Organization:
Haukeland University Hospital
Study Overview
Official Title:
Hepatitis C Treatment of Inmates A Randomized Open-label Study Evaluating the Feasibility Safety and Efficacy of Treatment With Peginterferon Alfa-2a in Combination With Ribavirin in Inmate Patients With Chronic Hepatitis C
Status:
TERMINATED
Status Verified Date:
2003-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Low inclusion rate
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PEGPRI
Brief Summary:
Hepatitis C infection is a prevalent chronic disease It is particularly prevalent among intravenous drug abusers Bergen fengsel is a regional prison housing 250 inmates of which as many as 70 are recorded HCV RNA PCR positive annuallly In this study inmate males and females will be randomized to standard screening and initiation procedure or to a rapid initiation procedure in the hospitals infectious diseases outpatient clinic The study aims at studying if rapid inclusion will increase the possibility to conclude treatment while the prisoner still is incarcerated thus improve the chances of reaching a sustained virologic response compared to standard inclusion where prisoners as other out patients will wait for inclusion for several months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None